John H. Sampson

36.8k citations

385 papers · 24.7k indexed · 10 hit papers · h-index 84

Genetics top 0.01%
Oncology top 0.1%
Immunology top 0.1%
Molecular Biology top 0.5%
Pulmonary and Respiratory Medicine top 0.2%

Co-authors: Darell D. Bigner Allan H. Friedman David A. Reardon Henry S. Friedman James E. Herndon Gary E. Archer Duane A. Mitchell Roger E. McLendon
Topics: Glioma Diagnosis and Treatment (164 papers)Immunotherapy and Immune Responses (118 papers)CAR-T cell therapy research (84 papers)
Cited by: Genetics Immunology Oncology
Journals: Nature New England Journal of Medicine Proceedings of the National Academy of Sciences
Partner nations: United States Germany Italy

In The Last Decade

John H. Sampson

368 papers receiving 24.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

2007 1.0k citations James J. Vredenburgh, Annick Desjardins et al. Journal of Clinical Oncology profile →
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

2020 946 citations David A. Reardon, Manmeet S. Ahluwalia et al. profile →
Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

2010 613 citations John H. Sampson, Amy B. Heimberger et al. Journal of Clinical Oncology profile →
Recurrent Glioblastoma Treated with Recombinant Poliovirus

2018 582 citations Annick Desjardins, James E. Herndon et al. profile →
Phase II Trial of Gefitinib in Recurrent Glioblastoma

2003 558 citations Jeremy N. Rich, David A. Reardon et al. Journal of Clinical Oncology profile →
Brain immunology and immunotherapy in brain tumours

2019 480 citations John H. Sampson, Peter E. Fecci et al. profile →
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

2015 471 citations Michael Weller, Mark R. Gilbert et al. profile →
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

2015 410 citations Duane A. Mitchell, Kristen A. Batich et al. profile →
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

2017 362 citations Gordana Vlahovic, Timothy F. Cloughesy et al. profile →
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

2015 313 citations David A. Reardon, Tibor Keler et al. profile →

Peers

Countries citing papers authored by John H. Sampson

Since Specialization

Citations

This map shows the geographic impact of John H. Sampson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John H. Sampson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John H. Sampson more than expected).

Fields of papers citing papers by John H. Sampson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John H. Sampson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John H. Sampson. The network helps show where John H. Sampson may publish in the future.

Co-authorship network of co-authors of John H. Sampson

This figure shows the co-authorship network connecting the top 25 collaborators of John H. Sampson. A scholar is included among the top collaborators of John H. Sampson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John H. Sampson. John H. Sampson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	IL-7–mediated expansion of autologous lymphocytes increases CD8+ VLA-4 expression and accumulation in glioblastoma models 2025 ·Journal of Clinical Investigation ·(unknown),Kelly Hotchkiss,Sarah Cook,(unknown),Ying Zhou,(unknown),(unknown),(unknown),(unknown),(unknown),Pamela K. Norberg,Gary E. Archer,Beth H. Shaz,Katayoun Ayasoufi,John H. Sampson,Mustafa Khasraw,Peter E. Fecci	1
2	Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma 2025 ·JAMA Network Open ·Émilie Le Rhun,(unknown),Sara Erridge,David A. Reardon,Giuseppe Minniti,Patrick Roth,Wolfgang Wick,Burt Nabors,John H. Sampson,Warren Mason,Timothy F. Cloughesy,J.C. Reijneveld,Roger Stupp,Matthias Preusser,Thierry Gorlia,Michael Weller	0
3	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement 2021 ·Clinical Cancer Research ·Stephen Bagley,Shawn Kothari,Rifaquat Rahman,Eudocia Q. Lee,Gavin P. Dunn,Evanthia Galanis,Susan M. Chang,Burt Nabors,Manmeet S. Ahluwalia,Roger Stupp,Minesh P. Mehta,David A. Reardon,Stuart A. Grossman,Erik P. Sulman,John H. Sampson,Simon Khagi,Michael Weller,Timothy F. Cloughesy,Patrick Y. Wen,Mustafa Khasraw	104
4	Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma 2020 ·Clinical Cancer Research ·Kristen A. Batich,Duane A. Mitchell,Patrick Healy,James E. Herndon,John H. Sampson	80
5	Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice 2019 ·Health Science Reports ·Annick Desjardins,James E. Herndon,Frances McSherry,Arliene Ravelo,Eric Lipp,Patrick Healy,Katherine B. Peters,John H. Sampson,Dina Randazzo,Nicolas Sommer,Allan H. Friedman,Henry S. Friedman	11
6	A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma 2018 ·Clinical Cancer Research ·Patrick C. Gedeon,Teilo Schaller,Satish K. Chitneni,Bryan D. Choi,Chien‐Tsun Kuan,Carter M. Suryadevara,David J. Snyder,Robert J. Schmittling,(unknown),Xiuyu Cui,Patrick Healy,James E. Herndon,Roger E. McLendon,Stephen T. Keir,Gary E. Archer,Elizabeth A. Reap,Luis Sánchez-Pérez,Darell D. Bigner,John H. Sampson	38
7	CD27 stimulation unveils the efficacy of linked class I/II peptide vaccines in poorly immunogenic tumors by orchestrating a coordinated CD4/CD8 T cell response 2018 ·OncoImmunology ·Katherine A. Riccione,Li-Zhen He,Peter E. Fecci,Pamela K. Norberg,Carter M. Suryadevara,Adam M. Swartz,Patrick Healy,Elizabeth A. Reap,Tibor Keler,Qi-Jing Li,Kendra L. Congdon,Luis Sánchez-Pérez,John H. Sampson	10
8	Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination 2017 ·Clinical Cancer Research ·Kristen A. Batich,Elizabeth A. Reap,Gary E. Archer,Luis Sánchez-Pérez,Smita K. Nair,Robert J. Schmittling,(unknown),Weihua Xie,James E. Herndon,Patrick Healy,Roger E. McLendon,Allan H. Friedman,Henry S. Friedman,Darell D. Bigner,Gordana Vlahovic,Duane A. Mitchell,John H. Sampson	242
9	Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors 2016 ·Cancer Research ·Fang Li,Xinjian Liu,John H. Sampson,Darell D. Bigner,Chuan‐Yuan Li	28
10	Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma 2015 ·Clinical Cancer Research ·Christina Pham,Catherine Flores,Changlin Yang,Elaine M. Pinheiro,Jennifer H. Yearley,Elias Sayour,Yanxin Pei,Colin E. Moore,Roger E. McLendon,Jianping Huang,John H. Sampson,Robert J. Wechsler‐Reya,Duane A. Mitchell	87
11	Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells 2014 ·Clinical Cancer Research ·Smita K. Nair,Gabriel De Leon,David Boczkowski,Robert J. Schmittling,Weihua Xie,Janet Staats,Rebecca Liu,Laura A. Johnson,Kent J. Weinhold,Gary E. Archer,John H. Sampson,Duane A. Mitchell	74
12	EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss 2013 ·Clinical Cancer Research ·John H. Sampson,Bryan D. Choi,Luis Sánchez-Pérez,Carter M. Suryadevara,David J. Snyder,Catherine Flores,Robert J. Schmittling,Smita K. Nair,Elizabeth A. Reap,Pamela K. Norberg,James E. Herndon,Chien-Tsun Kuan,Richard A. Morgan,Steven A. Rosenberg,Laura A. Johnson	241
13	The Addition of Bevacizumab to Standard Radiation Therapy and Temozolomide Followed by Bevacizumab, Temozolomide, and Irinotecan for Newly Diagnosed Glioblastoma 2011 ·Clinical Cancer Research ·James J. Vredenburgh,Annick Desjardins,David A. Reardon,Katherine B. Peters,James E. Herndon,Jennifer Marcello,John P. Kirkpatrick,John H. Sampson,Leighann Bailey,Stevie Threatt,Allan H. Friedman,Darell D. Bigner,Henry S. Friedman	112
14	Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastomabreakdown → 2010 ·Journal of Clinical Oncology ·John H. Sampson,Amy B. Heimberger,Gary E. Archer,Kenneth Aldape,Allan H. Friedman,Henry S. Friedman,Mark R. Gilbert,James E. Herndon,Roger E. McLendon,Duane A. Mitchell,David A. Reardon,Raymond Sawaya,Robert J. Schmittling,Weiming Shi,James J. Vredenburgh,Darell D. Bigner	613
15	An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme 2009 ·Molecular Cancer Therapeutics ·John H. Sampson,Gary E. Archer,Duane A. Mitchell,Amy B. Heimberger,James E. Herndon,Denise Lally-Goss,(unknown),(unknown),David A. Reardon,Allan H. Friedman,Henry S. Friedman,Darell D. Bigner	221
16	Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas 2008 ·Clinical Cancer Research ·Annick Desjardins,David A. Reardon,James E. Herndon,Jennifer Marcello,Jennifer A. Quinn,Jeremy N. Rich,Sith Sathornsumetee,Sridharan Gururangan,John H. Sampson,Leighann Bailey,Darell D. Bigner,Allan H. Friedman,Henry S. Friedman,James J. Vredenburgh	130
17	Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function 2007 ·Clinical Cancer Research ·Peter E. Fecci,Hidenobu Ochiai,Duane A. Mitchell,Peter M. Grossi,(unknown),Gary E. Archer,Thomas J. Cummings,James P. Allison,Darell D. Bigner,John H. Sampson	265
18	CONVECTION-ENHANCED DELIVERY OF CINTREDEKIN BESUDOTOX (INTERLEUKIN-13-PE38QQR) FOLLOWED BY RADIATION THERAPY WITH AND WITHOUT TEMOZOLOMIDE IN NEWLY DIAGNOSED MALIGNANT GLIOMAS 2007 ·Neurosurgery ·Michael A. Vogelbaum,John H. Sampson,Sandeep Kunwar,Susan M. Chang,Mark E. Shaffrey,Anthony L. Asher,Frederick F. Lang,David Croteau,Kristen Parker,Amy Grahn,Jeffrey W. Sherman,Syed R. Husain,Raj K. Puri	112
19	INTRACEREBRAL INFUSATE DISTRIBUTION BY CONVECTION-ENHANCED DELIVERY IN HUMANS WITH MALIGNANT GLIOMAS 2007 ·Operative Neurosurgery ·John H. Sampson,Martin Brady,Neil A. Petry,David Croteau,Allan H. Friedman,Henry S. Friedman,Terence Z. Wong,Darell D. Bigner,Ira Pastan,Raj K. Puri,Christoph Pedain	112
20	2 The Kennel Club and the Early History of Dog Shows and Breed Clubs 2006 ·Cold Spring Harbor Monograph Archive ·John H. Sampson,M. M. Binns	7

About John H. Sampson

John H. Sampson is a scholar working on Genetics, Immunology and Oncology, having authored 385 papers that have together received 24.7k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (164 papers), Immunotherapy and Immune Responses (118 papers) and CAR-T cell therapy research (84 papers). The work is most often cited by research in Genetics (11.7k citations), Immunology (7.8k citations) and Oncology (9.8k citations). John H. Sampson has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Darell D. Bigner, Allan H. Friedman, David A. Reardon, Henry S. Friedman, James E. Herndon, Gary E. Archer, Duane A. Mitchell, Roger E. McLendon, Peter E. Fecci and Amy B. Heimberger. Their work appears in journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact